These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15994128)

  • 21. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomic analysis of human sarcoma.
    Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
    Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
    Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.
    Valmori D; Souleimanian NE; Hesdorffer CS; Old LJ; Ayyoub M
    Clin Immunol; 2005 Nov; 117(2):161-7. PubMed ID: 16103015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
    Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.
    Romero P; Dutoit V; Rubio-Godoy V; Liénard D; Speiser D; Guillaume P; Servis K; Rimoldi D; Cerottini JC; Valmori D
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):766s-772s. PubMed ID: 11300471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
    Grah J; Samija M; Juretić A; Sarcević B; Sobat H
    Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast.
    Piatesi A; Howland SW; Rakestraw JA; Renner C; Robson N; Cebon J; Maraskovsky E; Ritter G; Old L; Wittrup KD
    Protein Expr Purif; 2006 Aug; 48(2):232-42. PubMed ID: 16563796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
    Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
    Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
    Mizote Y; Uenaka A; Isobe M; Wada H; Kakimi K; Saika T; Kita S; Koide Y; Oka M; Nakayama E
    Vaccine; 2014 Feb; 32(8):957-64. PubMed ID: 24397899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.
    Slager EH; van der Minne CE; Goudsmit J; van Oers JM; Kostense S; Havenga MJ; Osanto S; Griffioen M
    Cancer Gene Ther; 2004 Mar; 11(3):227-36. PubMed ID: 14726960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
    Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
    Uenaka A; Wada H; Isobe M; Saika T; Tsuji K; Sato E; Sato S; Noguchi Y; Kawabata R; Yasuda T; Doki Y; Kumon H; Iwatsuki K; Shiku H; Monden M; Jungbluth AA; Ritter G; Murphy R; Hoffman E; Old LJ; Nakayama E
    Cancer Immun; 2007 Apr; 7():9. PubMed ID: 17441676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.